CClinicalTrials.gg
WithdrawnNCT00064688Updated Sep 10, 2015

Genomic Dissection of a QTL Affecting the Lipid Profile

An observational study in Cardiovascular Diseases, Heart Diseases and Obesity, sponsored by Medical College of Wisconsin. Withdrawn. Per ClinicalTrials.gov, last updated 2015-09-10.

Sponsored by Medical College of Wisconsin · Observational

Why this study was withdrawn
This protocol was created to support work as part of an NIH-funded study.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
0
Sex
All
01

Study summary

To search for the genetic cause of the metabolic syndrome, a lipid disorder that poses a major risk for coronary heart disease.

Read the detailed description

BACKGROUND:

The metabolic syndrome is a common disorder posing a significant major risk for coronary heart disease and early mortality in the Western hemisphere. Central to its cardiovascular complications is the association of the syndrome with the specific abnormalities in plasma lipid and lipoprotein profiles including increased plasma triglycerides, decreased HDL cholesterol, and predominance of dense lipoprotein particles. In search for the genetic etiology of this lipid disorder, the investigators identified a quantitative trait locus (QTL) on human chromosome 7q36 strongly linked to variation in plasma lipid levels. They hypothesize that this QTL contains genetic variants that contribute to alterations in biologic pathways underlying the genesis of the lipid disorder.

DESIGN NARRATIVE:

The study will search for the genetic cause of the metabolic syndrome, a lipid disorder that poses a major risk for coronary heart disease. The investigators have identified a quantitative trait locus (QTL) on human chromosome 7q36 strongly linked to variation in plasma lipid levels. The investigators hypothesize that this QTL contains genetic variants that contribute to alterations in biologic pathways underlying the genesis of the lipid disorder. To test for this hypothesis, they propose a comprehensive approach utilizing established resources and expertise to identify the functional sequence variants within this QTL. Specifically, they will 1.) identify single nucleotide polymorphisms (SNPs) and their haplotype and linkage disequilibrium structure across the entire QTL region; 2.) Analyze association of informative SNPs with plasma triglyceride levels, LDL levels, and lipoprotein density fractions using variance component linkage/disequilibrium analyses; and 3.) Identify potentially functional sequence variants in associated genes or genomic regions using Bayesian quantitative trait nucleotide analysis. This comprehensive application of newly available genomic technologies, novel statistical approaches, the DNA and phenotypic information available, and the consortium of expertise assembled behind this project will ensure the successful elucidation of the genetic etiology of this lipid disorder and consequently the development of effective means for prevention and/or treatment of cardiovascular complications of the metabolic syndrome.

02

Conditions studied

  • Cardiovascular Diseases
  • Heart Diseases
  • Obesity
  • Hyperlipidemia, Familial Combined
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

Browse Cardiovascular Diseases studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 120 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

No eligibility criteria

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
0 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

Study locations

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00064688
Lead sponsor
Medical College of Wisconsin
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Jul 14, 2003
Start date
Jul 2003
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Sep 10, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion